Cetirizine

Cetirizine

SCHEMBL1647930

O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1.[Cl-].[Cl-].[H+].[H+]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HRH1

The experimentally established mechanism targets of Cetirizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH1 known ✓ P35367 4/20 0.95
▸ DRD3 P35462 5/20 0.95
▸ USP2 O75604 3/20 0.95
▸ HRH2 P25021 2/20 0.95
▸ HTR2A P28223 2/20 0.95
▸ HTR2B P41595 2/20 0.95
▸ KCNH2 Q12809 2/20 0.95
▸ TDP1 Q9NUW8 2/20 0.95
▸ SLC6A2 P23975 1/20 0.95
▸ SLC6A4 P31645 1/20 0.95
▸ SLC6A3 Q01959 1/20 0.95
▸ TEK Q02763 1/20 0.95
▸ DRD2 P14416 4/20 0.71
▸ ABCB11 O95342 1/20 0.71
▸ CHRM2 P08172 1/20 0.71
▸ ADRA2A P08913 1/20 0.71
▸ ADRA2B P18089 1/20 0.71
▸ ADRA2C P18825 1/20 0.71
▸ DRD4 P21917 1/20 0.71
▸ HTR7 P34969 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cetirizine SCHEMBL1231124 0.99 DRD3 (0.98) DRD3HRH1USP2HRH2HTR2A
Cetirizine SCHEMBL2455487 0.98 DRD3 (1.00) DRD3HRH1USP2HRH2HTR2A
Cetirizine SCHEMBL5526985 0.98 DRD3 (1.00) DRD3HRH1USP2HRH2HTR2A
Cetirizine SCHEMBL4176 0.98 DRD3 (1.00) DRD3HRH1USP2HRH2HTR2A
Cetirizine SCHEMBL13724610 0.98 DRD3 (1.00) DRD3HRH1USP2HRH2HTR2A
Levocetirizine SCHEMBL4914 0.98 DRD3 (1.00) DRD3HRH1USP2HRH2HTR2A
Levocetirizine SCHEMBL5935097 0.98 DRD3 (1.00) DRD3HRH1USP2HRH2HTR2A
Levocetirizine SCHEMBL2255374 0.97 HRH1 (1.00) DRD3HRH1USP2HRH2HTR2A
Levocetirizine SCHEMBL2432644 0.97 DRD3 (0.98) DRD3HRH1USP2HRH2HTR2A
Cetirizine SCHEMBL6474316 0.97 DRD3 (0.98) DRD3HRH1USP2HRH2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117821168-A Semiconductor chip cleaning liquid, preparation method and application thereof 浙江奥首材料科技有限公司 2024-04-05 — — CN disclosed
US-20220331257-A1 LIQUID PHARMACEUTICAL COMPOSITIONS WITH STABLE DRUG RELEASE PROFILES AVADEL LEGACY PHARMACEUTICALS, LLC 2022-10-20 — — US disclosed
US-20170001988-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2017-01-05 — — US disclosed
CN-106029060-A piperidine and piperidine derivatives and their use in the treatment of viral infections and cancer 美国卫生和人力服务部 2016-10-12 — — CN disclosed
US-7927613-B2 Pharmaceutical co-crystal compositions UNIVERSITY OF SOUTH FLORIDA (US) 2011-04-19 — — US disclosed
US-7790905-B2 Pharmaceutical propylene glycol solvate compositions MCNEIL-PPC, INC. (US) 2010-09-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170001988-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER NCOR1, RRP15, NCOA1 HRH1 100/4885DRD3 584/4885USP2 3001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback